Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ABBV
ABBV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ABBV ETF News Today | Earnings, Events & Price Alerts
ABBV News
ABBVIE: RISANKIZUMAB SC INDUCTION DEMONSTRATES A SAFETY PROFILE CONSISTENT WITH PREVIOUS FINDINGS IN CROHN'S DISEASE
1d ago
moomoo
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
1d ago
Barron's
AbbVie: A Strong Dividend Investment Choice
1d ago
Fool
AbbVie Increases Dividend by Over 330% Since IPO
1d ago
NASDAQ.COM
AbbVie Reports Promising Phase 3 Results for Crohn's Disease Treatment
1d ago
Benzinga
AbbVie's Skyrizi Subcutaneous Trial Achieves Key Milestones
1d ago
seekingalpha
AbbVie Reports Positive Phase 3 Results for Crohn's Disease Drug
1d ago
NASDAQ.COM
AbbVie Reports Positive Results for SKYRIZI in Crohn's Disease Treatment
1d ago
PRnewswire
AbbVie Reports Positive Phase 3 Results for Crohn's Disease Treatment Risankizumab
1d ago
Newsfilter
Wall Street Analyst Rating Updates
3d ago
seekingalpha
AbbVie's Outlook for the Next Five Years
5d ago
Fool
AbbVie's Positive Outlook for the Next Five Years
5d ago
NASDAQ.COM
RBC Capital Markets Initiates Outperform Rating on AbbVie
6d ago
seekingalpha
Enveric Biosciences Patent Challenge Withdrawn
6d ago
stocktwits
Enveric Biosciences Patent Challenge Withdrawn
6d ago
Benzinga
AbbVie Invests $380 Million to Expand Manufacturing in North Chicago
Feb 24 2026
Yahoo Finance
Show More News
